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Abstract
The MIC of cefepime determined with the MicroScan WalkAway system was ‡2 times higher than that of ceftazidime for 105 clinical
isolates of Pseudomonas aeruginosa. This phenotype was conﬁrmed by reference microdilution in 68 (64.8%) isolates, corresponding to
48 different rep-PCR patterns. The PSE-1 blactamase was identiﬁed in only 13.2% isolates, while oxacillinases were not identiﬁed in any
of the 68 isolates. The level of expression of mexB, mexD and mexY was determined by real-time RT-PCR in eight clinical isolates rep-
resentative of the different clones and patterns of susceptibility to cefepime and ceftazidime and in strain PAO1. All clinical strains over-
expressed the mexY gene (18.3- to 152.7-fold in comparison with PAO1), although there was not a linear relationship between MIC of
cefepime and level of mexY expression. Five of these strains contained mutations in the regulatory gene mexZ. mexD and mexB were
also overexpressed in three and two isolates, respectively. Different mutations were observed in the regulatory genes nalD, mexR, nfxB
and nalC. In conclusion, we have documented in our institution a polyclonal spread of P. aeruginosa with higher MICs of cefepime than
of ceftazidime, related to overexpression of MexXY-OprM, coincident in some isolates with the production of PSE-1, MexCD-OprJ or
MexAB-OprM.
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Introduction
MICs of cefepime against wild-type clinical isolates of Pseu-
domonas aeruginosa are usually similar to those of ceftazi-
dime [1]. However, strains intermediate or resistant to
cefepime and susceptible to ceftazidime have been
described [2–7]. This phenotype has been related to hyper-
production of the efﬂux system MexXY-OprM [2,5–7] and/
or the production of OXA-31 [3], OXA-35 [4] or PSE-1
[2,7]. Although the MexCD-OprJ system does not contrib-
ute to the basal natural resistance of P. aeruginosa [8], when
it is overexpressed it causes increased resistance to cefe-
pime and other compounds (ﬂuoroquinolones, macrolides,
etc.) [9]. However, MexCD-OprJ overexpression is uncom-
mon among clinical isolates of P. aeruginosa, with the nota-
ble exception of isolates from cystic ﬁbrosis patients. In a
previous study, none of 38 isolates more resistant to cefe-
pime than to cefazidime overexpressed the MexCD-OprJ
[2]. Also, in a collection of bacteraemic isolates, MexAB-
OprM and MexXY-OprM were overexpressed in 11% and
36% of the isolates, respectively, while MexCD-OprJ over-
expression was not detected in any isolate [10]. Similarly,
only 4 of 110 clinical isolates with decreased susceptibility
to ciproﬂoxacin hyperproduced MexCD-OprJ, and although
these four isolates were less susceptible to cefepime than
to ceftazidime, it was not possible to demonstrate the
direct involvement of this efﬂux system in the decreased
activity of cefepime [11].
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On the other hand, susceptibility testing of P. aeruginosa
to cefepime with several automatic systems has caused
either major errors (false resistance) or minor errors
(resulting from categorizing some isolates as intermediate to
cefepime when they actually were susceptible to this com-
pound) [12–16].
In our centre, using the MicroScan WalkAway system
(Dade Behring, Sacramento, CA, USA), we have obtained
during recent years clinical isolates of P. aeruginosa presenting
lower susceptibility to cefepime than to ceftazidime. The
objectives of this study were to conﬁrm this phenotype using
a standardized susceptibility testing assay and to describe the
molecular mechanisms involved.
Materials and Methods
Bacteria
One hundred and ﬁve consecutive clinical isolates of P. aeru-
ginosa isolated in the period September 2004 to June 2005,
for which the MIC of cefepime was ‡2 times higher than that
of ceftazidime, were collected from 99 patients (64 men and
35 women). During the study period, 1652 isolates of
P. aeruginosa, cultured from 780 patients, were obtained in
our centre; the 105 isolates we initially selected represent
6.4% of all isolates, and the 99 patients correspond to 12.7%
of all patients from whom P. aeruginosa was isolated. The
organisms were cultured from wound exudates (n = 44),
respiratory samples (n = 25), urines (n = 21), blood cultures
(n = 3) or ‘other’ (n = 12, including lung biopsy, semen and
sterile ﬂuids).
Identiﬁcation and susceptibility testing of the bacteria were
performed with the MicroScan Walkaway 96 system, using
Combo Neg 1S panels. Isolates were maintained at )80C in
tryptic soy broth with 10% glycerol. Organisms were plated
out twice on Mueller-Hinton agar plates (Difco) before addi-
tional studies were performed.
Susceptibility testing
MICs of both cefepime (Bristol Myers Squibb, Madrid, Espan˜a)
and ceftazidime (Sigma, Madrid, Espan˜a) against the indicated
105 isolates were determined by microdilution, according to
CLSI guidelines [17]. P. aeruginosa ATCC 27853 was included
as a control. The microdilution assay was performed three
times on three different days. The ﬁnal MIC values consid-
ered in this study were those corresponding to the modal
values for every isolate. Cefepime and ceftazidime suscepti-
bilities of the 105 isolates were also determined by the
disk-diffusion assay (CLSI guidelines), using 30-lg disks (BBL
Sensi-DiscTM, Becton-Dickinson, Franklin Lakes, NJ, USA).
Molecular typing
Clonal relationship of the isolates was evaluated by REP-
PCR, using primers described by Vila et al. [18]. Amplicons
were analysed by agarose gel electrophoresis. Two isolates
were considered clonally unrelated when two or more dif-
ferent bands were observed. Additionally, pulsed-ﬁeld gel
electrophoresis (PFGE) was performed in organisms present-
ing the same banding pattern or with only one band of differ-
ence. DNA agarose plugs were digested overnight with SpeI
(Roche Diagnostics, Indianapolis, IN, USA) at 37C. The
restriction fragments were separated on 1% w/v agarose gels
in 0.5% TBE buffer in a CHEF-DR II electrophoresis system
(Bio-Rad Laboratories, Richmond, CA, USA) for 26 h at
14C using a pulse ramping rate changing from 1 to 20 s at
6 V/cm. PFGE patterns were interpreted according to the
criteria by Tenover et al. [19].
Analysis of resistance mechanisms
Detection of genes coding for oxacillinases of groups I, II and
III and penicillinase PSE-1 was performed by PCR in the 68
isolates for which the phenotype here investigated was con-
ﬁrmed by reference microdilution (see below), using previ-
ously reported primers and conditions [20,21]. Amplicons
(both strands) were sequenced using an external resource
(Macrogen, Seoul, Korea).
The level of expression of mexB, mexD and mexY was
determined by real-time PCR (RT-PCR) in strain PAO1 and
in eight clinical isolates (representative of the different clones
and patterns of susceptibility to cefepime and ceftazidime),
including ﬁve, two and one isolates for which the MIC of
cefepime was higher than that of ceftazidime by 2, 4 or 16
times, respectively (Table 1). Total RNA was extracted with
the Rneasy Protect bacteria Mini Kit (QIAGEN, Hilden, Ale-
mania), according to manufacturer’s recommendations. DNA
was removed with RNase-Free DNase treatment and RNA
preparations were tested for the lack of Pseudomonas aerugin-
osa DNA contamination by PCR with primers speciﬁc for the
rpsL Pseudomonas gene. None of the RNA samples used in
the study ampliﬁed before cycle 35. RNA concentration was
determined spectrophotometrically and the quality of the
samples was checked in agarose gels in denatured conditions.
Quantiﬁcation of speciﬁc genes was performed by qPCR in a
two-step reverse transcription and real-time PCR using the
iScript cDNA synthesis kit and iQ SYBR Green supermix
(Bio-Rad). The rpsL gene was used as an internal reference
to normalize the relative amount of RNA. The experiment
was repeated in triplicate, using independent RNA extrac-
tions in every assay. The expression of the indicated genes
was compared with their expression in the PAO1 strain. The
genes were considered to be overexpressed when the
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amount of RNA was at least four times higher than that in
PAO1.
In the same set of eight strains, the sequences of the regu-
latory genes mexR, mexZ, nfxB, nalC and nalD were deter-
mined after their ampliﬁcation by PCR, using the primers
indicated in Table 2. Amplicons were sequenced, and the
BLAST program was used to compare the nucleotide and
protein sequences with those available on the http://
www.ncbi.nlm.nih.gov website.
Results and Discussion
Reference microdilution conﬁrmed that the MICs of cefe-
pime were ‡3, 2 and 1 twofold dilutions higher than that of
ceftazidime for 10 (9.5%), 35 (33.3%) and 23 (22%) of the
corresponding isolates. However, in 37 (35.2%) isolates the
MICs of cefepime were the same or one dilution lower than
those of ceftazidime. Interestingly, differences in the MIC of
cefepime by the reference and the commercial method did
not translate into either very major (false susceptibility) or
major (false resistance) errors, but in ﬁve (4.8%) isolates
caused a minor error (intermediate by reference microdilu-
tion and resistance by the automatic system). The same
clinical categories were obtained with microdilution and with
the standardized disk diffusion method, except for one iso-
late susceptible to cefepime by microdilution and resistant by
disk-diffusion and two other isolates susceptible to cefepime
by microdilution and intermediate by disk-diffusion. These
results support that identiﬁcation of P. aeruginosa strains
more resistant to cefepime than to ceftazidime with the
MicroScan WalkAway system is not completely reliable. This
agrees with multiple reports [12–16] indicating the difﬁculties
of automatic systems when testing cefepime against P. aeru-
ginosa.
There is scarce information on the clinical aspects related
to P. aeruginosa less susceptible to cefepime than to ceft-
azidime. Our isolates were obtained from a variety of clinical
samples, as already documented in another study [7].
The use of piperacillin-tazobactam has been reported as an
TABLE 1. MICs of ceftazidime and cefepime against clinical strains of Pseudomonas aeruginosa and expression of efﬂux pump
genes and amino acid variations in regulatory proteins of the corresponding organisms
Strain
MIC (mg/L) Efﬂux pump expression
blaPSE-1
Amino acid substitutions/mutations in regulatory proteins
CAZ FEP mexB mexD mexY MexZ NalD MexR NfxB NalC
HUMV_038 2 4 5.64 1 95.3 + nt 60T-G nt 85D16
nt 101D3
V126E R5G
K144I
G71E
E153Q
nt 123D1
nt t147D1
HUMV_039 2 4 1.08 18.1 93.3 ) L162R
nt 32171nt322
Wild-type V126E R33H
D68G
G71E
A145V
nt 586D1
HUMV_089 4 8 0.96 2 54.9 ) Wild-type Wild-type V126E w.t. G71E
HUMV_026 8 16 2.09 4 26.8 ) Not ampliﬁed Wild-type V126E
T130P
nt 40012nt 401
R33H
D68G
K144R N195I
G71E
A145V
nt 6111nt 612
HUMV_110 8 16 5.41 2.4 186.8 + nt 60T-G Wild-type V126E R5G G71E
E153Q
S209R
HUMV_057 4 16 0.81 150.5 18.3 ) Wild-type Wild-type w.t. R54C
nt 541D1
nt 600A-G
G71E
S209R
P210L
HUMV_111 16 64 1.1 1.7 152.7 ) G137D
G195R
Wild-type V126E w.t. G71E
HUMV_072 1 16 1.0 2.2 140 ) nt 5911nt 592 Wild-type V126E T7N G71E
A186T
TABLE 2. Primers for ampliﬁcation and expected amplicon sizes of genes involved in efﬂux system regulation
Efﬂux system Gene Primers Sequence (5¢–3¢) Expected size (pb)
MexCD-OprJ nfxB NfxB_F AAATGATCTTTTGACAGCTAATTCCT 760
NfxB_R ACTGATCTTCCCGAGTGTCG
MexAB-OprM mexR MexR_F TGTTCTTAAATATCCTCAAGCGG 729
MexR_R GTTGCATAGCGTTGTCCTCA
nalC NalC_F TCAACCCTAACGAGAAACGCT 813
NalC_R TCCACCTCACCGAACTGC
nalD NalD_F GCGGCTAAAATCGGTACACT 788
NalD_R ACGTCCAGGTGGATCTTGG
MexXY-OprM mexZ MexZB_F CCCTTGTGAGGACGTTCA 968
MexZB_R CCCAGAGCGATTGCAGATA
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independent risk factor for the acquisition of P. aeruginosa
with this phenotype [7]. It is possible that the use of quinol-
ones, which are good substrates for different efﬂux pumps
[8], may also select for strains with this phenotype.
The combined typing strategy of Rep-PCR/PFGE allowed
the identiﬁcation of 47 different clones, and organisms of the
same clone presented similar (±1 twofold dilution) MICs of
cefepime and ceftazidime. This polyclonal situation contrasts
with the results from another study in Spain, documenting
the expansion of a single clone affecting 51 patients [7].
Oxacillinase genes were not detected, while the blaPSE-1
gene was ampliﬁed in nine (13.2%) isolates. This indicates
that the polyclonal nature of our isolates is not due to hori-
zontal transmission of the genes encoding PSE-1 or an oxacil-
linase. The possible contribution of AmpC hyperexpression
in our isolates was ruled out by testing (by disk-diffusion)
both ceftazidime and cefepime in media with or without
cloxacillin (Sigma, 250 mg/L). The inhibition zones of cefazi-
dime did not change (‡5 mm) in the presence of cloxacillin
for any of the strains, while a change was observed for cefe-
pime in only three strains (none of which were any of the
eight isolates studied in detail).
The eight isolates studied in detail overexpressed mexY.
However, there was not a clear relationship between the
level of mexY expression and the MIC of cefepime. Only
three strains showed signiﬁcant levels of expression of mexD
with MIC values of ceftazidime/cefepime ranging from 2–8 to
4–16 mg/L (Table 1). These strains lack PSE-1 but as they
also displayed increased expression of mexY, it is rather difﬁ-
cult to deﬁne the actual contribution of either (or even
both) efﬂux system to the observed phenotypes. These three
isolates overexpressing both mexY and mexD had different
MIC values of cefepime and were not the ones with the
highest MICs of cefepime, suggesting that in addition to the
(plausible) role of MexXY-OprM and perhaps that of Mex-
CD-OprJ, other factors should be related in the strains we
studied. mexB was also overexpressed in two strains, but this
overexpression is likely to be unrelated to the studied phe-
notype (Table 1).
Among the eight strains studied in detail, HUMV_038 and
HUMV_110 expressed PSE-1, but it is difﬁcult to demon-
strate whether their susceptibilities to ceftazidime and cefe-
pime are due to MexXY efﬂux activity or PSE-1 expression.
Several mutations at DNA and protein levels were observed
in all the efﬂux system regulators we studied. In MexR, the
Val-126Glu substitution was found in seven of the eight
strains (Table 1). This previously described mutation [22–24]
was considered non-signiﬁcant as it was also observed in sus-
ceptible wild-type strains. Strain HUMV_026 carried a Thr-
130Pro substitution. A similar amino acid substitution at the
same position (Thr-130Ser) was described before [24] with
no signiﬁcant differences between susceptible and resistant
isolates. A frameshift mutation due to an insertion of 12 bp
between nucleotides 400 and 401 was also discovered in
strain HUMV_026. This mutation affects the C-terminal por-
tion of the protein including the stop codon TAA found in
PAO1, resulting in a larger peptide. Frameshift mutations in
MexR have already been reported related to MexAB-OprM
overexpression [22,25,26]. Nevertheless, this change does
not seem to considerably affect the ability of MexR to bind
the promoter region of mexAB-oprM or the way the repres-
sor protein modulates the expression of this operon, as no
high levels of expression were registered for mexB in strain
HUMV_026.
NalC, the repressor of ArmR (antirepressor for MexR)
displayed three recurrent amino acid substitutions: Gly-
71Glu, Glu-153Gln and Ser-209Arg. Such mutations have
also been described [25] and they seemed not to affect the
integrity of NalC. Three new amino acid substitutions were
observed in NalC, Ala-145Val, Pro-210Lys and Ala-186Thr,
but we could not associate them with changes in expression
of mexB. In strain HUMV_038, nalC shows two nucleotide
deletions at positions 123 and 147 generating a frameshift
affecting the N-terminal portion of the protein, which con-
tains the DNA binding domain (from residues 20 to 64). The
new protein has 149 amino acid residues instead of the 213
of the PAO1 strain. A 1-bp insertion in the nalC gene of
strain HUMV_026 at position 611 generates a frameshift
mutation that affects the C-terminal extreme of the protein
from residue Lys-203. Strain HUMV_039 has one nucleotide
deletion in nalC at position 586 creating a frameshift that
affects its C-terminal portion of the protein from residue
Ser195. It is difﬁcult to correlate the effects of the single
base changes in nalC of HUMV_026 and HUMV_039 with
changes in expression of MexB. In strain HUMV_110 the
combination of mutations in both proteins (MexR, Val-
126Glu; NalC, Gly-71Glu, Glu-153Gln and Ser-209Arg) may
be related to the increased levels of MexB expression.
Mutations in nalD were only observed in strain
HUMV_038, which displayed a 16 bp deletion at nucleotide
85 and a 3 bp deletion at position 101. Both deletions affect
the N-terminal portion of the protein that contains the
DNA binding domain, generating a truncated peptide. These
changes together with those found in NalC may be responsi-
ble for MexB overexpression in this strain. A previous study
also showed that the combined action of mutations in mexR,
nalC and nalD may be responsible for the overexpression of
MexAB-OprM [24].
mexZ presented several mutations in ﬁve of eight strains.
Several attempts to amplify mexZ in strain HUMV_026 were
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unsuccessful, suggesting that this strain lacks this gene, possi-
bly due to a deletion. This can also explain the overexpres-
sion of MexY. Two isolates (HUMV_038 and HUMV_110)
had a substitution of one nucleotide at position 60 (GAG for
TAG), which generates a premature stop codon resulting in
a truncated peptide, lacking the ﬁrst 28 residues where a
fragment of the DNA binding domain (from residues 15 to
60) is present in wild-type strains. This mutation could cor-
relate with MexY overexpression (Table 1). The mexZ gene
of strain HUMV_039 has an insertion of 71 bp between nu-
cleotides 321 and 322. This sequence is almost identical
(only differs in 1 bp) to a sequence placed immediately
upstream, ﬂanked by two imperfect direct repeats of 12 bp
G(C)GGT(C)GCTGGACA that most likely caused such
sequence duplication. This mutation could also explain the
high levels of expression of mexY (93.3-fold higher) when
compared with that of PAO1 (Table 1). The strain
HUMV_072 presented an insertion of 1 bp in mexZ between
nucleotides at positions 591 and 592. This insertion leads to
a frameshift that affects the C-terminal extreme of MexZ
from Asp-297 and may explain the high levels of expression
of mexY and consequently the MIC values of cefepime
(16 mg/L) observed in this strain (Table 1). The Gly-195Arg
substitution is similar to one formerly described (Gly-
195Glu) that correlated with overexpression of mexY and
high MIC values of FEP in clinical strains of P. aeruginosa [2].
Other mutations observed in MexZ were single amino acid
substitutions: Leu-162Arg (strain HUMV_039) and Gly-
137Asp plus Gly-195Arg (strain HUMV_111). The mexZ gene
of strains HUMV_089 and HUMV_057 did not show any
mutations; however, mexY was overexpressed in both strains
(Table 1), which may be due to mutations in additional medi-
ators that control the expression of mexXY, as previously
suggested in other studies [25,27,28].
Several different amino acid substitutions in NfxB, the
repressor of MexCD-OprJ, have been identiﬁed. The amino
acid substitutions Arg-33His and Asp-68Gly were previously
described in clinical strains of P. aeruginosa [24,29] but with
different residue numbers (Arg-21His and Asp-56Gly, respec-
tively). This is probably due to a miss-annotation of nfxB,
hence the differences in the residue positions reported. In
this study we have assumed that the start codon of the nfxB
gene might be 36 nts upstream of the ‘proposed’ ATG, con-
sidering that the sequence AGGCCAG within the bounds of
the gene (12 bp upstream of the ATG) is more likely to be a
ribosome binding site of this gene. In addition, the size of
this ‘corrected sequence’ is similar to that of its homolog
genes in other P. aeruginosa strains such as PA7 or even to
that of other pseudomonads like P. syringae B728a. These
two amino acid substitutions (Arg-21His and Asp-56Gly)
were found to be related to ciproﬂoxacin resistance [29]. In
the strain HUMV_057 a deletion of 1 bp in nfxB at position
541 leads to a frameshift mutation affecting the C-terminal
portion of NfxB from residue N180. Beside this there is a
single base pair substitution at position 600, affecting the
stop codon (TGA for TGG), which translates into a protein
larger than the one in the wild-type PAO1. Interestingly,
mutations in the stop codon, leading to a longer predicted
NfxB, have also been documented among MexCD-OprJ
hyperproducing mutants in vitro and in animal models of
infection [30].
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